ASCENDIS PHARMA A/S: Financial statements 2014
CVR: 29918791
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
ASCENDIS PHARMA A/S (CVR 29918791) has filed annual accounts for 2014. In 2014, the company reported revenue of EUR 13,983,000 and a net result of EUR -9,658,000. The profit margin was -69.1%. Equity in the 2014 report amounted to EUR 45,810,000. The solvency ratio was 78.1%.
- Revenue
- EUR 13,983,000
- Profit/Loss
- EUR -9,658,000
- Equity
- EUR 45,810,000
- Total Assets
- EUR 58,671,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | 14 mio. EUR | - | -9.7 mio. EUR | 45.8 mio. EUR | - |
| 2012 | 118.5 mio. | 63.7 mio. | 8.9 mio. | 134.6 mio. | 38 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
As of November 26, 2014, Jonathan Silverstein has joined the board of directors of ASCENDIS PHARMA A/S.
As of November 26, 2014, Jim Healy has joined the board of directors of ASCENDIS PHARMA A/S.
As of November 26, 2014, Albert Cha has joined the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2013.
As of June 2, 2014, Martin Olin has joined the board of directors of ASCENDIS PHARMA A/S.
As of June 2, 2014, Edwin William de Graaf has joined the board of directors of ASCENDIS PHARMA A/S.
As of April 15, 2014, Dirk Kersten has left the board of directors of ASCENDIS PHARMA A/S.
As of April 1, 2014, William Robert Ringo has left the board of directors of ASCENDIS PHARMA A/S.
As of January 27, 2014, Thomas Paul Soloway is registered as økonomidirektør of ASCENDIS PHARMA A/S.
About ASCENDIS PHARMA A/S
ASCENDIS PHARMA A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA ApS and CADENZA PARTNERS ApS. The management consists of Jan Møller Mikkelsen, Anni Lotte Kirstine Pedersen and Michael Wolff Jensen. The board consists of Albert Cha (chair), Jan Møller Mikkelsen, Jean-Jacques Bienaime and Lars Holtug. The company is owned by Cede & Co. The company has 688 employees (2026). In 2025, the company reported revenue of EUR 720,132,000 and a net result of EUR -228,034,000 compared with EUR -378,084,000 the year before. Equity in the 2025 report amounted to EUR -162,821,000.